Lesson plan
Toreforant
Toreforant (JNJ-38518168) is an orally-dosed selective antagonist of the histamine H 4 receptor that has been studied for various health conditions. It is the successor of a number of H 4 -selective compounds developed by Johnson & Johnson. Phase IIa clinical trials completed as recently as November 2018 continue to suggest that toreforant is safe. As of the end of 2020, there is no regulator-approved H 4 antagonist. In U.S. Phase II clinical trials, toreforant, by itself, did not show efficacy against eosinophilic asthma. The drug did show at least partial efficacy against rheumatoid arthritis in patients who were nonresponsive to methotrexate. As the H 4 receptor is widely implicated in the regulation of inflammatory states, the potential uses for an H 4 antagonist remain significant.
Article summary
Toreforant (JNJ-38518168) is an orally-dosed selective antagonist of the histamine H 4 receptor that has been studied for various health conditions. It is the successor of a number of H 4 -selective compounds developed by Johnson & Johnson. Phase IIa clinical trials completed as recently as November 2018 continue to suggest that toreforant is safe. As of the end of 2020, there is no regulator-approved H 4 antagonist. In U.S. Phase II clinical trials, toreforant, by itself, did not show efficacy against eosinophilic asthma. The drug did show at least partial efficacy against rheumatoid arthritis in patients who were nonresponsive to methotrexate. As the H 4 receptor is widely implicated in the regulation of inflammatory states, the potential uses for an H 4 antagonist remain significant.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.